Skip to content
Back to meeting Original
Rashid K. Sayyid· @RKSayyid · X·· 21 hours agoScore70

durvalumab

Body

#ESMO26 RAMPART: What do detailed PROs show with adjuvant durvalumab vs active monitoring after RCC resection?

PRO analysis, n=218 (Durvalumab: 87; Active monitoring: 131)

🚨 Primary QoL endpoint at Mo 15 showed no difference between arms—but domain-level analyses told a different story.

At Week 16, durvalumab worsened:
🔹 OHQL: –7.4
🔹 Role function: –7.1
🔹 Cognitive function: –5.3
🔹 Fatigue: +5.5
🔹 Appetite loss: +5.8

At Mo 15:
🔹 Cognitive function remained worse: –7.1
🔹 Appetite loss: +7.4
🔹 Dyspnea: +7.5
🔹 Constipation: +12.2

🔑 A global QoL endpoint may miss clinically meaningful treatment effects across individual domains—some occurring during therapy, some persisting, and others emerging later.

@urotoday

10 views · 0 likes · 0 reposts · 0 replies

Conference abstracts
2879ROmatched by Rapid oral 1: Gastrointestinal tumour, upper digestive

Durvalumab plus definitive chemoradiotherapy versus definitive chemoradiotherapy in patients with locally advanced esophagus carcinoma: ARION PRODIGE 67 randomized phase 2 trial

https://esmocongress.esmo.org
4737ROmatched by Rapid oral 1: Genitourinary tumours, renal and urothelial

Durvalumab (D) in Combination With BCG Induction and Maintenance (I+M) for BCG-Naïve, High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC): Early Recurrence and Cystectomy-Free Survival in Patients (pts) With Papillary Only Tumours From POT

https://esmocongress.esmo.org
LBA2matched by Presidential Symposium I

Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial

https://esmocongress.esmo.org
LBA26matched by Proffered paper 2: Breast cancer, early and advanced stage

Short-term preoperative durvalumab for stage I TNBC: First results from the phase II UNLOCK 14 - POP-DURVA trial

https://esmocongress.esmo.org
LBA3matched by Presidential Symposium I

Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial

https://esmocongress.esmo.org
LBA37matched by Proffered paper: Gynaecological cancers

Durvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): Interim overall survival (OS) and safety from the randomised phase 3 DUO-E/GOG-3041/ENGOT-EN10 stud

https://esmocongress.esmo.org

Source: Rashid K. Sayyid · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.